January 29, 2015
New Jersey-based biopharmaceutical company Immunomedics Inc. on Thursday turned back allegations that it misled investors by concealing the deterioration of a major licensing agreement after a federal judge ruled the company was under no obligation to disclose anything short of the contract's termination to investors.